Note: Descriptions are shown in the official language in which they were submitted.
WO 2014/197859
PCT/US2014/041405
1
MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF
[0001] This application claims the benefit of priority under 35 U.S.C.
119
of U.S. Provisional Application No. 61/832,302, filed June 7,2013
[0002] The present disclosure relates to methods of screening,
diagnosing,
monitoring and/or treating acid sphingomyelinase (ASM) disorders such as
Niemann-Pick disease.
[0003] Acid sphingomyelinase (ASM) is a lysosomal phosphodiesterase
enzyme that hydrolyzes sphingomyelin (SPM), a phospholipid storage substance
found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and
phosphorylcholine. Loss of ASM activity can result in the inability of the
body to
break down SPM. In patients with ASM disorders, SPM accumulates predominantly
in macrophages, but also within hepatocytes and other cell types, resulting in
marked hepatosplenomegaly, thrombocytopenia, interstitial lung disease, and
coronary artery disease. SPM is not significantly elevated in plasma, whole
blood, or
urine, rendering it of limited use as a non-invasive biomarker.
[0004] Diagnosis of an ASM disorder currently requires invasive
testing
and/or time-consuming medical examination, such as an evaluation of suspected
clinical signs and symptoms, liver or lung biopsy, testing for ASM activity in
a blood
sample (where false negative and positive cases have been reported), and/or
genetic testing (e.g., SMPD1 gene mutation analysis). Treatment of ASM
disorders
can include administration of replacement enzyme. At high doses, enzyme
replacement therapy can result in the production of toxic or harmful
metabolites.
Accordingly, there is a need to develop improved methods for screening,
diagnosing
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
2
and/or monitoring the course of treatment for an ASM disorder. Disclosed
herein are
methods of non-invasively screening, diagnosing, monitoring therapy, and/or
adjusting the dose of a therapeutic agent for treating an ASM disorder,
comprising
measuring the level of lyso-SPM (sphingosylphosphorylcholine or lyso-
sphingomyelin) in a biological sample. Elevated levels of lyso-SPM can be used
to
screen for or diagnose an ASM disorder. Elevated levels of lyso-SPM can also
be
used as a signal or indication of the production of one or more toxic
metabolites
associated with an excessively high dose of enzyme replacement therapy,
thereby
allowing for the calibration of enzyme therapy to reduce the buildup of SPM
while
avoiding harmful side-effects of the therapy. Elevated levels of lyso-SPM can
also
be used to monitor the long-term efficacy of a course of treatment for an ASM
disorder (e.g., if levels of lyso-SPM do not decrease over the course of
treatment,
this can indicate an ineffective treatment).
[0005] Niemann-Pick disease (NPD) is an inherited, autosomal recessive
lipid storage disorder characterized by excessive accumulation of SPM in the
lysosomes of cells such as macrophages and neurons, which impairs normal
cellular
function. Niemann-Pick Type A ("NPD-A") is a rapidly progressive
neurodegenerative disease in infants and typically results in death within two
to three
years of age. Niemann-Pick Type B ("NPD-B") results in the enlargement of the
liver
and spleen, and respiratory distress with death generally ensuing by early
adulthood.
Other types of Niemann-Pick disease, e.g., Type C ("NPD-C"), may also be
associated with accumulation of SPM and/or lyso-SPM. They are also referred to
herein as ASM disorders (ASMD). These forms of Niemann-Pick disease are
collectively referred to herein as Niemann-Pick disease (NPD).
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
3
[0006] NPD occurs more frequently among individuals of Ashkenazi
Jewish ancestry than in the general population. It is estimated that the
incidence of
NPD-A among Ashkenazi Jews is about 1 in 40,000, with a gene frequency (q) of
about 1 in 200 and a heterozygote carrier frequency (2 pq) of 1 in 100
(Goodman,
1979, in "Genetic Disorders Among The Jewish People", John Hopkins Univ.
Press,
Baltimore, pp. 96-100). The heterozygote carrier incidence of NPD-B in the
Ashkenazi Jewish population is less frequent. Id. The combined heterozygote
carrier frequency for NPD A and B has been estimated to be about 1 in 70 among
individuals of Ashkenazi Jewish decent. Id. In epidemiologic studies conducted
in
various countries, the combined incidence of NPD A and B disease in several
countries in the world is estimated to range from 1 in 167,000 to 1 in 250,000
newborns (Miekle et al., 1999 JAMA 281(3):249-254; Poorthuis et al., 1999 Hum.
Genet. 105:151-156; Pinto et al., 2004 Euro. J. Hum. Gene. 12:87-92). The
heterozygote carrier rate is believed to range from 1 in 200 to 1 in 250
individuals.
[0007] Patients with either NPD-A or NPD-B have residual ASM activity
(about 1 to 10% of normal), but this is not sufficient to prevent the
excessive
accumulation of sphingomyelin in the lysosomes. Moreover, the clinical course
of
NPD-B is highly variable, and it is not presently possible to correlate
disease severity
with the level of residual ASM activity. Although the enzymatic diagnosis of
affected
patients with either NPD-A or NPD-B can be made in blood samples, this
diagnosis
is often preceded by invasive procedures such as liver or lung biopsy. In
addition,
the enzymatic detection of obligate heterozygotes has proven problematic,
particularly using peripheral leukocytes as the enzyme source. One possibility
is that
the occurrence of neutral sphingomyelinases in some sources and/or the
presence
of residual ASM activity resulting from the mutant alleles have contributed to
the
WO 2014/197859
PCT/US2014/041405
4
inability to reliably discriminate carriers for either disease subtype. Even
the use of
cultured skin fibroblasts, which do not express the neutral sphingomyelinase,
has not
provided unambiguous results with heterozygotes. Accordingly, alternative
methods
for accurately detecting, screening, diagnosing, and treating ASM disorders,
such as
NPD, are needed.
[0008] Enzyme replacement therapy (ERT) has been used to treat various
lysosomal storage diseases. See, e.g., U.S. Patent 7,001,994 and U.S. Patent
Application No. 2011/0052559, discussing ERT for Tay-Sachs, Pompe, and
Niemann-Pick disease, among others
ERT attempts to supplement the deficient and/or defective enzyme with
exogenously
supplied enzyme. In the case of ERT for Niemann-Pick disease, the goal would
be
to enable the affected individual to process sphingomyelin and avoid its
buildup
within the lysosomes. To be effective, such therapy can initially require a
sufficiently
large amount of the replacement enzyme to break down the accumulated
sphingomyelin, as well as continued administration of replacement enzyme to
avoid
subsequent re-accumulation of sphingomyelin. The metabolism of accumulated
sphingomyelin can, however, result in the production of toxic or harmful
metabolites.
Careful coordination of ERT is needed, therefore, to effectively debulk
accumulated
sphingomyelin in a patient without producing elevated levels of metabolite
that may
result in adverse side effects.
[0009] As noted previously, SPM is not significantly elevated in
plasma,
whole blood, or urine, rendering it of limited use as a non-invasive biomarker
to
screen, diagnose or monitor treatment for an ASM disorder. As disclosed
herein,
lyso-SPM (sphingosylphosphorylcholine or lyso-sphingomyelin), the deacylated
form
of SPM, is significantly elevated in tissues, including peripheral tissues, in
patients
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
suffering from and/or being treated for ASM disorders, making it a potential
marker
for screening, diagnosing, and/or monitoring treatment for an ASM disorder.
This
dichotomy is in contrast to many other lysosomal storage disorders, where
altered
levels of both the acylated and deacylated glycosphingolipids are detectable
in
plasma. Given that altered levels of SPM are not detectable in plasma from
patients
suffering from or being treated for ASM disorders, it might have been expected
that
lyso-SPM would likewise not be suitable for screening, diagnosis, or
monitoring of
treatment. However, as disclosed herein, it has been found that lyso-SPM can
be
detected at altered levels in biological samples from various tissues,
including
peripheral tissues such as blood plasma.
[0010] Lyso-sphingolipids (lyso-SL), which include lyso-SPM, are the
deacylated forms of sphingolipids; several have been shown to be elevated in
certain
lysosomal storage disorders. Galbiati et al., "Combined hematopoietic and
lentiviral
gene-transfer therapies in newborn Twitcher mice reveal contemporaneous
neurodegeneration and demyelination in Krabbe disease," J. Neurosci. Res. 87:
1748-1759 (2009). The mechanism by which lyso-SPM and other lyso-SL are
produced has not been fully elucidated. The lack of a concurrent elevation in
sphingosine suggests that deacylation of the corresponding sphingolipid is the
likely
route of generation. However, the only sphingomyelin deacylase identified to
date is
from the stratum corneum of an atopic dermatitis subject. Murata et al.,
"Abnormal
expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor
for
ceramide deficiency?", J. Invest. Dermatol. 106: 1242-1249 (1996). The
expression
of this deacylase appears to be limited to selected cell types under certain
physiological conditions. Purified ASM from placenta, brain, and urine has
been
shown not to hydrolyze lyso-SPM. Pentchev et al., "The isolation and
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
6
characterization of sphingomyelinase from human placental tissue," Biochim.
Biophys. Acta. 488: 312-321 (1977); Yamanaka and Suzuki, "Acid
sphingomyelinase
of human brain: purification to homogeneity," J. Neurochem. 38: 1753-1764
(1982);
Ouintern et at., "Acid sphingomyelinase from human urine: purification and
characterization," Biochim. Biophys. Acta. 922: 323-336 (1987). The lack of
understanding regarding the biosynthetic pathway for lyso-SPM further
emphasizes
the difficulty in predicting its expression level a priori in patients
suffering from ASM
disorders.
[0011] Lyso-SPM has a short half-life in blood in vitro because of its
rapid
metabolism to sphingosine-1-phosphate through autotaxin, an exoenzyme with
lysophospholipase D activity. Tokumura et al., "Identification of human plasma
lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a
multifunctional phosphodiesterase," J. Biol. Chem. 277: 39436-39442 (2002);
Clair et
al., "Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the
regulator of
migration, sphingosine-1-phosphate," Cancer Res. 63: 5446-5453 (2003). Other
than in spleen and liver of NPD-B patients, and the brains of NPD-A subjects
who
have little to no ASM activity and manifest severe neuropathic disease, there
are no
reports on the level of lyso-SPM in other organs.
[0012] As disclosed herein, lyso-SPM can be detected at altered
concentrations in biological samples (e.g., samples taken from peripheral
tissues)
from patients suffering from and/or being treated for ASM disorders. The
altered
level can reflect a transient effect of treatment (e.g., altered lyso-SPM
levels can
serve as a marker for the production of acute toxic metabolites in response to
ERT).
The altered levels can also be used diagnostically (e.g., altered lyso-SPM
levels can
serve as a diagnostic or screening marker to identify a symptomatic or pre-
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
7
symptomatic subject suffering from an ASM disorder). The altered levels can
also
be used to monitor the long-term efficacy of a course of treatment for an ASM
disorder (e.g., if levels of lyso-SPM do not decrease over the course of
treatment,
this can indicate an ineffective treatment). Accordingly, disclosed herein are
new
methods of screening, diagnosing, monitoring the progression of treatment,
and/or
adjusting the dose of a therapeutic agent for treating an ASM disorders such
as NPD
using novel biomarkers including lyso-SPM (sphingosylphosphorylcholine or lyso-
sphingomyelin). Monitoring the course of treatment can include detecting a
reduction in the level of one or more marker of toxicity (e.g., lyso-SPM) over
the
course of treatment, thereby indicating an effective treatment regime, or
detecting a
lack of change in the level of the marker over time, thereby indicating an
ineffective
regime.
[0013] The methods disclosed herein also include methods of treating a
human subject having an acid sphingomyelinase (ASM) disorder. In certain
aspects,
the methods can comprise administering to the subject a first dose of a
therapeutic
agent for treating an ASM disorder having a first concentration; and
administering to
the subject a second dose of therapeutic agent having a second concentration
equal
to or greater than the first concentration if the subject has been determined
to have a
level of lyso-SPM that is less than or equal to a reference level after
administration of
the first dose. The methods can include the measurement of lyso-SPM in
biological
samples from peripheral tissues and the identification of a patient suffering
from an
ASM disorder by detecting altered lyso-SPM levels. The methods also include
monitoring or adjusting a patient's treatment for an ASM disorder by detecting
the
level of one or more toxicity markers, including lyso-SPM, that are altered as
a result
of treating the patient with a therapeutic agent, e.g., an agent that reduces
the level
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
8
of SPM in the patient's tissues. The methods allow for the non-invasive
evaluation of
such patients.
[0014] The methods disclosed herein can also be used, in some
embodiments, to screen, diagnose, monitor the progression of treatment, and/or
adjust treatment for an ASM disorder, such as NPD. For example, the methods
include adjusting the dose of a therapeutic agent given to a patient to treat
an ASM
disorder by measuring a toxicity marker (e.g., lyso-SPM) in order to manage
the
levels of toxic metabolites resulting from treatment. The methods disclosed
herein
can be used, in some embodiments, to monitor the long-term efficacy of a
course of
treatment for an ASM disorder (e.g., if levels of lyso-SPM do not decrease
over the
course of treatment, this can indicate an ineffective treatment). The methods
can
also be used, in some embodiments, to screen subjects (e.g., patients who are
pre-
symptomatic) for elevated lyso-SPM as an initial indication of an ASM
disorder.
Subjects identified as having elevated lyso-SPM in screening could then be
given
additional evaluation (e.g., ASM blood testing, genetic testing, etc.) to
diagnose/confirm a diagnosis of an ASM disorder, while those subjects who did
not
exhibit elevated lyso-SPM would not be given additional evaluation. Such a
screening method could potentially reducing testing costs.
[0015] The methods disclosed herein can include the measurement of
lyso-SPM in a biological sample from a human subject and the administration of
a
therapeutic agent for treating an ASM disorder (e.g., ERT, chaperone therapy,
and/or substrate reduction therapy) at optimized concentrations based on the
measured level of lyso-SPM. In various embodiments, the biological sample is a
peripheral sample. In certain embodiments, the biological sample can be a
sample
of plasma, whole blood (e.g., dried blood spot), serum, and/or urine. Use of a
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
9
peripheral sample to measure lyso-SPM levels can avoid the need for invasive
procedures such as liver biopsy.
DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1A is a plot showing the ratio of SPM concentration in dried
blood spots (DBS) from NPD-A and NPD-B patients to the mean concentration
value
in DBS from normal control samples. FIG. 1B is a plot showing the ratio of
lyso-SPM
concentration in DBS from NPD-A and NPD-B patients to the mean concentration
value in DBS from normal control samples.
[0017] FIG. 2 is a histogram showing the fold elevation in lyso-SPM
concentrations (vertical axis) in DBS from ASM knockout mice at the indicated
time
points (1, 2, 4, 6, 24, 48, and 72 hours post-dose), as compared to the
concentration
minutes after a single dose administration of 0, 3, or 20 mg/kg rhASM.
[0018] FIG. 3 shows the concentration of lyso-SPM (ng/ml) in DBS
obtained from wild type (C57BL/6) or ASM knockout (ASMKO) mice following
administration of a single dose (10 mg/kg) or a debulking dosing regimen (3
mg/kg)
followed by a dose of 20 mg/kg of rhASM. Blood samples were taken at the
following time points: 5 minutes, 4 hours, 6 hours, 24 hours, and 72 hours
post dose.
The animals in the 10 mg/kg dosing group had to be euthanized after the 24
hour
time point.
[0019] FIG. 4 is a histogram showing the concentration of lyso-SPM
(ng/ml) in DBS from a human Niemann-Pick patient collected pre-dose, and 24,
48,
and 72 hours after administration of a dose of rhASM over a 26 week period.
The
doses (0.1, 0.3, 0.6, 1, 2, or 3 mg/kg) and administration date (day 1, week
2, 4, 6, 8,
10, 12, 14, and 26) are indicated on the horizontal axis. At 26 weeks, samples
were
taken only pre-dose and at 24 and 48 hours post dose.
WO 2014/197859
PCT/US2014/041405
DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS
[0020] Reference will now be made in detail to certain exemplary
embodiments according to the present disclosure, certain examples of which are
illustrated in the accompanying drawings. Wherever possible, the same
reference
numbers will be used throughout the drawings to refer to the same or like
parts.
[0021] In this application, the use of the singular includes the
plural unless
specifically stated otherwise. In this application, the use of "or" means
"and/or"
unless stated otherwise. Furthermore, the use of the term "including", as well
as
other forms, such as "includes" and "included," is not limiting. Any range
described
herein will be understood to include the endpoints and all values between the
endpoints.
[0022] The section headings used herein are for organizational
purposes
only and are not to be construed as limiting the subject matter described. All
documents, or portions of documents, cited in this application, including but
not
limited to patents, patent applications, articles, books, and treatises
[0023] Disclosed herein are methods of screening, diagnosing,
monitoring
the progression of treatment, and/or adjusting the dose of a therapeutic agent
for
treating an ASM disorder, such as NPD. An "ASM disorder" can encompass any
disorder associated reduced expression or impaired function of acid
sphingomyelinase. An ASM disorder can also encompass any other disorder
associated with accumulation of sphingomyelin in a tissue.
[0024] In some embodiments, the methods can comprise administering to
the subject a first dose of a therapeutic agent for treating an ASM disorder
having a
first concentration; and then administering to the subject a second dose of
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
11
therapeutic agent having a second concentration equal to or greater than the
first
concentration if the subject has been determined to have a level of lyso-SPM
that is
less than or equal to a reference (e.g., the level in a sample from a control
subject
who does not have an ASM disorder, or the baseline level measured in the
patient
before treatment) level after administration of the first dose.
[0025] In certain aspects, the methods comprise collecting and measuring
lyso-sphingomyelin (lyso-SPM) in a biological sample from a human subject. The
measured level of lyso-SPM can be used to screen, diagnose, monitor the
progression of treatment, and/or adjusting the dose of a therapeutic agent for
treating an ASM disorder. The methods are based on the discovery that lyso-SPM
is
significantly elevated in biological samples from peripheral tissues of
patients with
ASM disorders such as NPD, allowing for the non-invasive evaluation of such
patients, including screening for and diagnosing an ASM disorder and
monitoring/calibrating/managing therapy for an ASM disorder. The methods are
also
based on the discovery that the breakdown of accumulated ASM during treatment
can lead to elevated levels of markers (e.g., lyso-SPM) that signal the
production of
toxic or harmful metabolites, and that these harmful levels of metabolites can
be
avoided by a method of administering a therapeutic agent designed to reduce
the
levels of SPM (e.g., ERT, chaperone therapy and/or substrate reduction
therapy) at
doses that prevent excessive metabolite production. The measurement of
elevated
concentration of lyso-SPM can be used to detect the production of such
metabolites
and can be used to calibrate therapy to avoid the production of excessively
elevated
levels of metabolite (e.g., toxic levels). In certain embodiments, the level
of lyso-
SPM in a patient receiving treatment for an ASM disorder determines whether
the
dose is increased, decreased, repeated, delayed, or discontinued.
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
12
[0026] The detection of elevated lyso-SPM levels in a subject having an
ASM disorder (e.g., NPD patients) can be used as part of a method of
monitoring for
an adverse side effect during treatment. For example, the method can comprise
collecting a biological sample from the subject, measuring a level of lyso-
sphingomyelin (lyso-SPM) in the sample, comparing the measured level of lyso-
SPM
in the sample to a reference level, and detecting an adverse side effect if
the level of
lyso-SPM in the sample is elevated. In some embodiments, if the level of lyso-
SPM
is elevated by a predetermined amount as compared to a reference sample (e.g.,
a
reference level in a sample from a control subject who does not have an ASM
disorder), or if the level of lyso-SPM increases by a predetermined amount in
the
subject over time during the course of treatment (i.e., an increase over the
baseline
level measured in the patient before treatment, also referred to herein as a
reference
level), then the measured level of lyso-SPM can be used as an indication of an
adverse side effect from the treatment. In some embodiments, the treatment is
enzyme replacement therapy (ERT) and the dosage of ERT is managed by
collecting one or more biological samples from the patient, testing each
sample for
an elevation in lyso-SPM, and setting the dose of ERT to a level that does not
produce elevated lyso-SPM levels above a predetermined threshold. Managing the
dose of a therapeutic agent can include increasing, decreasing, or maintaining
the
concentration of a therapeutic agent, and/or discontinuing treatment. In
certain
embodiments, one or more biological samples are collected after a dose of a
therapeutic agent is administered and/or just before the administration of a
subsequent dose of a therapeutic agent. In some embodiments, an adverse side-
effect can be detected if the level of lyso-SPM in the biological sample
(e.g., a blood
sample such as plasma, serum, or a dried blood spot) is greater than a
reference
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
13
level of about 100-700 ng/ml (e.g., greater than about 100, 200, 250, 300,
400, 500,
600, or 700 ng/ml, or any concentration inbetween), or if the level of lyso-
SPM in the
biological sample increases by at least about 1.1, 1.5, 2, 2.5, 3, 3.5, 4,
4.5, 5, 5.5, 6,
6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 fold, or more (or any value inbetween) over
a
reference level. For instance, the increase may be at least about 3 fold. The
reference level can be, e.g., the level in a sample from a control subject who
does
not have an ASM disorder or the baseline level measured in the patient before
treatment with a dose of the therapeutic agent.
[0027] Also disclosed herein are methods of treating a subject having an
ASM disorder (e.g., NPD). In various embodiments, the method comprises
administering a therapeutic agent for treating an ASM disorder (e.g., ERT,
chaperone therapy, and/or substrate reduction therapy) in sequential doses of
increasing concentration and monitoring the subject for elevated lyso-SPM
levels in
a biological sample after each dose (e.g., 1 minute, 5 minutes, 10 minutes, 30
minutes, or 45 minutes, or 1, 2, 3, 4, 5, 10, 12, 15, or 20 hours, or 1 day, 2
days, 5
days, 1 week, 2 weeks, 3 weeks, or 4 weeks after dosing, or any time period in
between), or just prior to the next dose. The monitoring of the subject can
comprise
collecting a biological sample from the subject, measuring the level of lyso-
SPM in
the sample, comparing the level of lyso-SPM in the sample to a reference level
(e.g.,
the level in a sample from a donor who does not have an ASM disorder, or the
level
in an ASM patient prior to treatment), and detecting an elevated lyso-SPM
level in
the sample as compared to the reference level. In some embodiments, the
reference level is the level of lyso-SPM measured in a biological sample from
a
control subject who does not have an ASM disorder. In some embodiments, the
reference level is the level of lyso-SPM measured in a sample from the subject
taken
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
14
after the administration of an earlier, lower dose of ERT or before
administration of
any ERT. In some embodiments, an elevated level of lyso-SPM in the biological
sample (e.g., a blood sample such as a serum sample, plasma sample, or dried
blood spot) is a level greater than a reference level of, e.g., about 100-700
ng/ml. In
some embodiments, an elevated level of lyso-SPM in the biological sample
(e.g., a
blood sample) is a level greater than a reference level by at least about 1.1,
1.5, 2,
2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 fold, or
more (or any value
in between). For instance, the level may be greater by a factor of at least
about 3.
In some embodiments, a higher concentration dose of ERT is not administered if
an
elevated level of lyso-SPM is detected after administration of a previous
dose.
[0028] In addition to monitoring therapy and therapeutic methods,
disclosed herein are methods of screening for and/or diagnosing an ASM
disorder
(e.g., NPD) in a subject. In various embodiments, the method comprises
collecting a
biological sample from the subject, measuring a level of lyso-SPM in the
sample,
comparing the level of lyso-SPM in the sample to a reference level, and
detecting/diagnosing an ASM disorder if the level of lyso-SPM in the sample is
elevated relative to the reference sample. In some embodiments, the reference
sample is a sample from a control subject who does not have an ASM disorder.
In
some embodiments, an ASM disorder can be screened for and/or diagnosed if the
level of lyso-SPM in the biological sample (e.g., a blood sample such as a
plasma
sample, serum sample, or dried blood spot) is higher than a reference level by
at
least about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9,
9.5, or 10 fold,
or more (or any value inbetween), or higher than a reference level of at least
about
200-2000 ng/ml, such as at least about 200 ng/ml, at least about 250 ng/ml, at
least
about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, at least
about
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
525 ng/ml, at least about 575 ng/ml, at least about 700 ng/ml, and/or at least
about
900 ng/ml (e.g., greater than about 200, 250, 300, 350, 400, 450, 500, 525,
550,
575, 600, 625, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150,
1200,
1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 ng/ml, or any concentration
in
between). In some embodiments, a biological sample from a normal subject may
contain a lyso-SPM level in the range of about 25-200 ng/ml (e.g., about 25,
50, 75,
100, 125, 150, 175, or 200 ng/ml, or any concentration in between).
Measurement of Lyso-SPM
[0029] For a discussion of the chemical structure of lyso-SPM, see,
e.g.,
Ito et al., J. Biol. Chem. 270: 24370-4 (1995); see also Caymen Chemical Co.
Item
Number 10007947, as offered in their catalog at:
https://www.caymanchem.com/app/template/Product.vm/catalog/10007947.
[0030] The methods disclosed herein involve the measurement of lyso-
SPM from various biological samples, including samples from peripheral
tissues.
Any methods for collecting, preparing, and quantifying the level of lyso-SPM
from a
biological sample can be used. The level of lyso-SPM in a biological sample
can be
quantified using a spectrometer, such as a mass spectrometer, e.g., LC/MS/MS,
or
an electromagnetic frequency spectrometer, e.g., UV-VIS, IR, or NMR. In some
embodiments, the method of quantifying the level of lyso-SPM can comprise
collecting a biological sample (e.g., by arterial or venous puncture, tissue
biopsy,
buccal swab, urine sample, etc.), detecting and/or separating the lyso-SPM
from the
other components of the sample (e.g. using an antibody, an indicator chemical,
a
mass spectrometer such as LC/MS/MS, or an electromagnetic frequency
spectrometer such as UV-VIS, IR, or NMR), and comparing the level of lyso-SPM
to
the level in a reference sample.
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
16
[0031] Lyso-SPM levels can be measured in biological samples from
various tissues with the methods described herein. For example, biological
samples
from peripheral tissues, such as plasma, whole blood (e.g., dried blood spot),
serum,
skin, and/or urine can be collected for use in detecting elevated lyso-SPM
levels.
Biological samples from other tissues can also be used, e.g., spleen, lung,
heart,
liver, kidney and/or brain tissue. Samples from combinations of two or more
tissues
can be used (e.g., 2, 3, 4, 5, or more tissues). In some embodiments, the use
of a
biological sample from a peripheral tissue can avoid the need for invasive
procedures such as a liver biopsy.
[0032] In some embodiments, the biological sample is subjected to one or
more pretreatment steps prior to the detection and/or measurement in the
sample of
lyso-SPM. In certain embodiments, the sample is pretreated by centrifugation,
filtration, precipitation, dialysis, or chromatography, or by a combination of
such
pretreatment steps. In other embodiments, the sample is pretreated by
freezing,
chemical fixation, paraffin embedding, dehydration, permeabilization, and/or
homogenization, followed by centrifugation, filtration, precipitation,
dialysis, and/or
chromatography. In certain embodiments, the sample is pretreated by removing
cells of a certain type from the sample or removing debris from the sample
prior to
the evaluation of lyso-SPM.
[0033] In various embodiments, the biological sample is evaluated using
a
device for quantifying or semi-quantifying the level of one or more marker in
the
sample. For example, the level of lyso-SPM and/or other markers in the sample
can
be evaluated quantitatively or semi-quantitatively. In some embodiments, a
device
for quantifying the level of lyso-SPM and/or other markers in a biological
sample,
such as a tandem liquid chromatography-mass spectrometry (e.g., LC/MS/MS), can
WO 2014/197859
PCT/US2014/041405
17
be used. In some embodiments, one or more antibodies or other detection agents
can be used to bind the lyso-SPM and/or other marker in the biological sample.
One
or more agents (e.g., a colorimetric agent) can be applied that reacts with
the
detection agent to emit a detectable signal whose strength, intensity, color,
etc. can
be used to semi-quantitatively or quantitatively determine the level of lyso-
SPM
and/or other markers in a sample (e.g., by comparison to the signal from one
or
more reference samples). Additional methods for quantifying lyso-SPM and/or
other
markers in a biological sample can also be used, e.g., immunoassays such as
ELISA, immunoprecipitation, and western blot, as well as fluorescence-
activated cell
sorting (FACS), fluorescence resonance energy transfer (FRET), RI-FOR, and/or
Northern blot methods.
Managing Treatment of an ASM Disorder
[0034] In various embodiments, lyso-SPM levels can be measured as part
of a therapy for an ASM disorder. For example, the ASM disorder can be Niemann-
Pick disease (NPD), e.g., NPD-A, NPD-B, or NPD-C. The therapy for an ASM
disorder can comprise the administration of one or more therapeutic agents
that
reduces the levels of SPM in the tissues of a patient (e.g., ERT, chaperone
therapy,
and/or substrate reduction therapy). For example, a within-patient dose-
escalation
enzyme replacement therapy (ERT) method can be used, such as the ASM dose-
escalation methods disclosed in U.S. Application No. 2011/0052559
(see, for example, paragraphs [0063]-
[0075], describing dose escalation protocols).
[0035] In various embodiments, a method is disclosed for monitoring a
subject for an adverse side effect (e.g., production of toxic or harmful
levels of
metabolites) by monitoring a marker such as lyso-SPM during a dose escalation
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
18
therapy for an ASM disorder. The method can comprise collecting a biological
sample from the subject, measuring the level of lyso-SPM in the sample,
comparing
the level of lyso-SPM in the sample to a reference level, and detecting an
adverse
side effect if the level of lyso-SPM in the sample is elevated as compared to
the
reference sample. One or more samples can be collected and evaluated after
administration of a dose of therapeutic agent, or prior to the administration
of the
next dose. For example, samples can be collected and evaluated 1 minute, 5
minutes, 10 minutes, 30 minutes, or 45 minutes, or 1, 2, 3, 5, 10, 12, 15, or
20 hours,
or 1, 2, 3, 4, 5 days, or 1, 2, 3, or 4 weeks after administration of a
therapeutic dose,
or any time period in between, or prior to administration of the next dose. In
some
embodiments, the reference sample is a sample from a control subject who does
not
have an ASM disorder. In some embodiments, the reference sample is an earlier
biological sample from the subject prior to the administration of a higher
concentration dose of therapeutic agent (or prior to administration of any
therapeutic
agent). In some embodiments, if the level of lyso-SPM increases by a
predetermined amount or above a predetermined threshold after administration
of an
initial dose or after administration of an increased (i.e., higher
concentration) dose of
therapeutic agent (e.g., a higher concentration of ERT), as compared to the
level in a
reference sample, then this can be used as an indication of an adverse side
effect
from the treatment. In certain embodiments, if the level of lyso-SPM does not
increase or does not increase above a threshold level, then can be used as an
indication that an adverse side effect has not occurred.
[0036] In various embodiments, a therapy for an ASM disorder is
provided.
The therapy can comprise the administration of one or more therapeutic agents
that
reduces the level of SPM in the tissues of a patient (e.g., ERT, chaperone
therapy,
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
19
and/or substrate reduction therapy). In certain embodiments, the therapy can
comprise ERT (e.g., ASM replacement therapy). The therapy can comprise
monitoring the subject for elevated levels of lyso-SPM during therapy and
adjusting
the concentration of therapeutic agent (e.g., the concentration of a dose of
ERT) to
reduce the lyso-SPM levels below a pre-determined threshold level. In some
embodiments, monitoring comprises evaluating a sample for elevated levels of
lyso-
SPM after each dose of therapeutic agent or prior to administration of each
subsequent dose of therapeutic agent. In certain embodiments, monitoring after
each dose is optional, and is conducted periodically after certain doses of
therapeutic agent or prior to administration of certain subsequent dose of
therapeutic
agent.
[0037] In some embodiments, therapy can comprise administering an ERT
(e.g., ASM replacement therapy) in sequential doses of increasing
concentration,
collecting biological samples from the patient after certain doses (e.g.,
after each
dose or prior to each subsequent dose), detecting a level of lyso-SPM in the
sample
(e.g., using LC/MS/MS), and monitoring the subject for elevated lyso-SPM
levels
after each dose or prior to administration of the next dose. For example, the
biological samples can be collected and monitored for elevated lyso-SPM at 1
minute, 5 minutes, 10 minutes, 30 minutes, or 45 minutes, or 1, 2, 3, 5, 10,
12, 15, or
20 hours, or 1, 2, 3, 4, 5 days, or 1, 2, 3, or 4 weeks after a dose of ERT is
administered, or at any time period in between, or prior to administration of
the next
dose. Monitoring the subject can comprise collecting a biological sample from
the
subject, measuring a level of lyso-SPM in the sample, comparing the level of
lyso-
SPM in the sample to a reference level, and adjusting the dose of ERT if the
level of
lyso-SPM in the sample is elevated by a predetermined amount as compared to
the
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
reference sample. In some embodiments, the reference sample is a sample from a
control subject who does not have an ASM disorder. In some embodiments, the
reference sample is an earlier biological sample from the subject prior to the
administration of a higher concentration dose of ERT (or prior to the
administration of
any ERT). In some embodiments, if the level of lyso-SPM increases by a
predetermined amount in the subject sample and/or is higher than a reference
threshold, then this can be used as an indication that the ERT dosage should
be
reduced, delayed, or terminated to avoid the production of toxic or harmful
levels of
metabolite. In some embodiments, if the level of lyso-SPM is at or below the
threshold, than a subsequent dose of equal or higher concentration can be
administered.
[0038] In various embodiments, a dose escalation therapy is provided,
comprising administering ERT to a subject at increasing doses over time to
debulk
accumulated SPM without producing toxic or harmful levels of metabolite
resulting
from the rapid hydrolysis of the accumulated SPM. In some embodiments,
biological
samples from the patient are monitored for elevated levels of lyso-SPM during
the
dose escalation therapy, as elevated lyso-SPM would indicate the production of
toxic
or harmful levels of metabolite. In some embodiments, if levels of lyso-SPM
above a
threshold concentration are detected, or a large increase in lyso-SPM levels
as
compared to levels in a previous sample are detected, then an increased dose
of
ERT is delayed or not administered. The ERT can be administered by any route
suitable for achieving a therapeutic effect, including intravenously,
intradermally,
subcutaneously, intraperitoneally, intrapulmonary, topically, intranasally,
intracranially, or intramuscularly.
WO 2014/197859
PCT/US2014/041405
21
[0039] In some embodiments, the ERT can comprise administration of an
acid sphingomyelinase (ASM), such as a recombinant human ASM (rhASM), or the
ERT can comprise administration of a modified ASM (e.g., modified rhASM). A
modified ASM can comprise any modification to the enzyme that does not
significantly alter its ability to hydrolyze lysosomal sphingomyelin to
ceramide and
phosphorylcholine (e.g., the modified ASM exhibits at least about 20, 30, 40,
50, 60,
70, 80, 90, 95, 99, 99.5, or 99.9% of the enzyme activity of unmodified ASM,
or any
percentage in between). The hydrolytic ability of a modified ASM can be
assessed
by techniques known to one of skill in the art, such as those described in
U.S. Pat.
Nos. 4,039,388, 4,082,781, 5,686,240, and 7,563,591, and International
Publication
Nos. WO 2007/078806 and WO 2006/058385
[0040] In some embodiments, the ERT can comprise administration of
recombinant human ASM (rhASM) or a modified rhASM. There are various human
ASM isoforms known in the art, all of which can be used in the methods
disclosed
herein. See, e.g., U.S. Application No. 2011/0052559
(see, e.g., the discussion of human ASM isoforms and
enzyme conjugates thereof and their use in ERT at paragraphs [108]-[0117] and
[0124]-[0127]).
[0041] In some embodiments, the enzyme replacement therapy is
administered to a subject at an initial low, non-toxic dose that is then
escalated in
subsequent administrations. The highest dose of enzyme that the subject can
tolerate without producing toxic or harmful levels of metabolite (as detected
by, e.g.,
monitoring the levels of a toxicity marker such as lyso-SPM) can then be used
as a
maintenance dose. Alternatively, a therapeutically effective dose less than
the
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
22
highest tolerated dose can be used as a maintenance dose. A therapeutically
effective dose can comprise any dose that is sufficient to reduce the
concentration of
accumulated sphingomyelin in an ASM subject by at least about 5, 10, 15, 20,
25,
30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 99% (or any
percentage in
between) after one or more rounds of administration.
[0042] Treatment of ASM disorders, such as NPD, require high enough
doses of therapeutic agent (e.g., ERT, chaperone therapy, and/or substrate
reduction therapy) to achieve adequate distribution of the therapeutic agent
in the
organs of pathology (e.g., the spleen, lungs, liver, heart, kidney and brain).
It has
been shown that, following intravenous administration of recombinant human ASM
in
ASM knockout mice, most of the ASM activity distributes to the liver, with
small
amounts of ASM enzymatic activity detected in other organs, such as the
spleen,
heart, liver, kidney and lung. See, e.g., He et al., Biochimia et Biophsyica
Acta 1432:
251-264 (1999). Thus, doses having an elevated concentration of therapeutic
agent
(e.g., high concentrations of replacement enzyme) may be required to ensure
adequate distribution and delivery to, e.g., the lung, liver, heart and kidney
in
subjects having an ASM disorder, such as NPD.
[0043] Studies in ASM knockout mice have also demonstrated that
enzyme replacement therapy may, at sufficiently high doses, result in the
production
of toxic or otherwise harmful metabolites of sphingomyelin. See, e.g., C.
Nickerson,
et al., American Society of Human Genetics (2005); and J. Murray et al.,
Society of
Toxicology (2006). Without being bound by theory, the administration of high
doses
of ASM to NPD subjects may result in the hydrolysis of large amounts of
accumulated sphingomyelin into ceramide and phosphorylcholine. Ceramide is
known to play a role in cell death and may be a pro-apoptotic agent. See,
e.g.,
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
23
Smith and Schuchman, FASEB 22: 3419-3431 (2008). Thus, ceramide may
contribute to the toxic side effects observed in the ASM knockout mice and in
NPD
subjects.
[0044] Thus, a calibration and coordination of therapy (e.g., ERT,
chaperone therapy, and/or substrate reduction therapy) is needed in order to
provide
a sufficient concentration of therapeutic agent to debulk and prevent future
accumulation of lysosomal sphingomyelin throughout the organs of pathology,
while
also avoiding the production of excessive concentrations of toxic metabolites.
In
some embodiments, this coordination is provided through managing a dose-
escalation protocol by evaluating the levels of a toxic marker, such as lyso-
SPM in a
patient sample after certain doses or after every dose and, if necessary,
adjusting
the dosing regimen as described herein. Managing the dose of a therapeutic
agent
can include increasing, decreasing, or maintaining the concentration of a
therapeutic
agent, and/or discontinuing treatment.
[0045] In various embodiments, a dose escalation method of treatment
involves the administration of one or more initial, low doses of therapeutic
agent
(e.g., replacement enzyme) to a subject to reduce the amount of sphingomyelin
that
has accumulated in the subject. The dose of therapeutic agent can then be
administered at systematically higher concentrations until the highest dose
that is
tolerated by the subject and is therapeutically effective is reached. In some
embodiments, the therapeutic agent is replacement enzyme (e.g., rhASM) and is
administered such that enzyme activity in one or more organs of pathology
(e.g., an
organ that exhibits elevated lysosomal levels of SPM in a patient suffering
from an
ASM disorder) is at least about 5%, 6%, 7%, 8%, 9%, 10%, 12%, 15%, 20%, 25%,
30%, 35%, 40%, 50%, 75%, 80%, 85%, 90%, 95% (or any percentage in between)
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
24
of the activity level of activity in the corresponding organ in a subject who
does not
suffer from an ASM disorder (e.g., a healthy subject).
[0046] In some embodiments, a method of treating an ASM disorder can
comprise: (a) administering an enzyme replacement regimen for debulking
accumulated sphingomyelin substrate in the subject comprising: (i)
administering an
initial low dose of rhASM or a modified rhASM to the subject; and (ii)
administering
successively higher doses of rhASM or a modified rhASM to the subject (dose
escalation); (b) monitoring the subject for elevated lyso-SPM levels and/or
for one or
more additional marker of an adverse side effect after certain doses, or after
each
dose, administered in steps (a)(i) and (a)(ii) (e.g., using LC/MS/MS to
quantify the
lyso-SPM concentration); (c) repeating, decreasing, and/or terminating the
dose
escalation protocol after elevated lyso-SPM levels are detected and/or after
one or
more additional adverse side effect is detected. In certain embodiments, the
method
further includes administering a maintenance regimen comprising administering
a
dose equal to or less than the highest dose tolerated by the subject as the
maintenance dose, and optionally further monitoring for elevated lyso-SPM
levels
during administration of the maintenance regime. In certain embodiments, the
initial
dose of rhASM or a modified rhASM can range from about 0.03 mg/kg to about 1.0
mg/kg, or about 0.1 mg/kg to about 0.5 mg/kg (the concentration of a dose is
measured as mg enzyme to kg body weight). In some embodiments, each
subsequent dose of increased enzyme concentration is administered about 1, 2,
3,
4, 5, 6, or 7 days, or 1, 2, 3, 4, or 5 weeks after the previous dose. In some
embodiments, the subsequent dose of increased enzyme can be at a concentration
of between about 0.1 and 5 mg/kg (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6,
0.7, 0.8,
0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg/kg, or any concentration in
between).
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
[0047] In some embodiments, a dose of replacement enzyme at a given
concentration is administered at least twice (e.g., at least 2, 3, 4, or 5
times) before
the next higher concentration dose is administered. In certain embodiments,
the
successively higher dose can be approximately 0.03 mg/kg, 0.05 mg/kg, 0.1
mg/kg,
0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg,
0.9
mg/kg, 1 mg/kg, 1.2 mg/kg, 1.5 mg/kg, 1.75 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg or
5
mg/kg higher than the previous dose (or any value in between). In some
embodiments, the successively higher dose can be about 0.03 to about 0.1
mg/kg,
about 0.1 mg/kg to about 0.5 mg/kg, about 0.5 mg/kg to about 1 mg/kg, about
0.5
mg/kg to about 2 mg/kg, about 1 mg/kg to about 2 mg/kg, about 2 mg/kg to about
4
mg/kg, or about 2 mg/kg to about 5 mg/kg higher than the previous dose (or any
value in between). In certain embodiments, the highest dose tolerated by the
subject
without production of toxic or harmful metabolites can be about 1.0 mg/kg to
about
3.0 mg/kg. In some embodiments, the highest tolerated dose is subsequently
administered to the human subject as a maintenance dose. In some embodiments,
the maintenance dose is administered about every 1 to 8 weeks (e.g., about
every 1,
2, 3, 4, 5, 6, 7, or 8 weeks, or any time period in between).
[0048] Once a maximum tolerated dosage is identified (e.g., a dose that
does not produce toxic or otherwise harmful levels of metabolite), it can be
used as a
maintenance dose to treat the subject going forward. The maintenance dose can
be
administered daily, weekly, biweekly, monthly, bimonthly or quarterly (or any
time
interval in between). Monitoring for elevated lyso-SPM levels can be conducted
during administration of the maintenance regime, e.g., 1, 2, 3, 5, 10, 12, 15,
or 20
hours, or 1, 2, 3, 4, 5 days, or 1, 2, 3, or 4 weeks after administration of a
maintenance dose, or any time period in between. If elevated lyso-SPM levels
are
WO 2014/197859
PCT/US2014/041405
26
detected (e.g., levels greater than a reference level of about 100-700 ng/ml,
or levels
at least about 1.1-10 fold greater than a reference level), then the
maintenance dose
can be reduced or discontinued.
[0049] Certain other
parameters can be measured in combination with
lyso-SPM to monitor a subject during therapy (e.g., during ERT) and/or as part
of the
therapy to determine the maximal dose that can be tolerated by the subject.
For
example, the subject can be further monitored by measuring SPM levels, plasma
ceramide levels, and/or bilirubin concentrations. The subject can also be
monitored
for the production of "acute phase reactants" and inflammatory mediators that
are a
measure of inflammatory responses, and/or for other biochemical markers. These
other biochemical markers can include, but are not limited to, CRP/hs-CRP,
cytokines (e.g., 1L-8, 11-6), calcitonin, and ferritin. In some embodiments,
one or
more of the parameters listed above can be monitored to ensure a stable
response
to therapy before elevating the dose to a higher concentration. In some
embodiments, the subject can also be monitored for one or more related adverse
events, which may include constitutional symptoms (e.g., fever, nausea,
vomiting,
pain, myalgia and jaundice). Combinations of markers can also be monitored
(e.g.,
lyso-SPM levels in combination with bilirubin and/or ceramide levels can be
monitored). Suitable threshold levels for the markers that can be monitored in
combination with lyso-SPM are disclosed, for example, in U.S. Application No.
2011/0052559, (see, for
example, paragraphs [0067]-[0086]).
[0050] In some
embodiments, a subject undergoing a dose escalation
protocol (e.g., an ERT dose escalation protocol) is monitored for toxic or
harmful
side-effects (e.g., by monitoring levels of one or more toxicity markers, such
as lyso-
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
27
SPM) after each round of therapeutic administration (e.g., about 1 minute, 5
minutes,
minutes, 30 minutes, or 45 minutes, or 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, or 24
hours,
or 2, 3, 4, 5, 6, or 7 days, or 1, 2, 3, or 4 weeks or more after
administration, or any
time period in between), or prior to administration of a higher concentration
of
therapeutic agent. In some embodiments, the subject is monitored after each
administration of a maintenance dose (e.g., about 1, 2, 3, 4, 5, 6, 8, 10, 12,
18, or 24
hours, or 2, 3, 4, 5, 6, or 7 days, or 1, 2, 3, or 4 weeks or more after
administration,
or any time period in between), or prior to administration of a subsequent
maintenance dose of therapeutic agent. In some embodiments, a subject receives
a
maintenance dose for one, two, three or more years and is monitored
periodically for
toxic or harmful side-effects. The monitoring can comprise monitoring the
toxicity
markers mentioned above, as well as monitoring for related adverse events. If
the
subject experiences an adverse event or if one or more of the monitored
markers
indicates a harmful side-effect (e.g., if an elevated level of lyso-SPM is
detected),
then the administration of the maintenance dose can be terminated or adjusted
(e.g.,
a reduced concentration of ERT can be administered) in order to reduce or
minimize
the undesirable side-effect.
[0051] In various embodiments, a subject can be monitored for a toxic
and/or otherwise harmful dose of ERT by measuring lyso-SPM levels from a
biological sample obtained after administration of a dose of ERT (e.g., after
administration of rhASM or modified rhASM). In some embodiments, the method
can comprise collecting a biological sample from the subject, measuring the
level of
lyso-SPM in the sample, comparing the level of lyso-SPM in the sample to a
reference level, and detecting an adverse side effect if the level of lyso-SPM
in the
sample is elevated as compared to the reference sample or elevated by a
particular
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
28
amount as compared to the reference sample. In some embodiments, the next dose
of ERT at a higher concentration is only administered if the level of lyso-SPM
in the
biological sample is not above a defined threshold after administration of the
previous dose. Examples of suitable threshold levels are described herein. In
some
embodiments, levels of lyso-SPM are also monitored during administration of
the
maintenance dose. In some embodiments, if the level of lyso-SPM exceeds a
defined threshold during administration of the maintenance dose, then the
maintenance administration is discontinued or a lower dose is administered
that
does not result in a level of lyso-SPM above the defined threshold.
[0052] In some embodiments, an adverse side-effect of ERT can be
detected if the level of lyso-SPM in the biological sample is higher than a
predetermined reference level. In some embodiments, an adverse side-effect can
be detected if the level of lyso-SPM in the biological sample (e.g., a blood
sample) is
greater than a reference level of about 100-700 ng/ml (e.g., greater than
about 100,
200, 250, 300, 400, 500, 600, or 700 ng/ml, or any concentration inbetween).
In
some embodiments, an adverse side-effect can be detected if the level of lyso-
SPM
in the biological sample (e.g., a blood sample) is higher than a reference
level by at
least about 1.1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5,
9, 9.5, or 10
fold, or more (or any value inbetween). For instance, the increase may be at
least
about 3 fold.
[0053] In some embodiments, the methods for treating ASM disorders
provided herein reduce spleen volume as assessed by techniques known in the
art,
e.g., MRI. In certain embodiments, the methods reduce liver sphingomyelin
levels
as assessed by techniques known in the art, e.g., biochemical analysis and/or
histomorphometric analysis of liver samples. In some embodiments, the methods
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
29
increase exercise capacity as assessed by techniques known in the art, e.g.,
maximum workload by cycle ergometry, including percent predicted maximum
workload, peak oxygen consumption, and/or carbon dioxide production. In some
embodiments, the methods increase pulmonary function and/or improve lung
clearance, as assessed by techniques known in the art, e.g., DLco, FVC, FEV,
and/or TLC. In certain embodiments, the methods decrease bronchial alveolar
lavage (BAL) sphingomyelin. In certain embodiments, the methods improve lung
appearance as assessed by techniques known in the art, e.g., high resolution
CT
scan and/or chest X-ray.
[0054] In various embodiments, the methods for treating ASM disorders
provided herein decrease sphingomyelin concentration in the liver, skin,
and/or
plasma, and/or reduce serum chitotriosidase, CCL18 levels, lyso-SPM, ceramide,
and/or bilirubin. In some embodiments, the methods improve a subject's lipid
profile
(e.g., decreased cholesterol). In some embodiments, the methods improve one or
more neurological function in a subject (e.g., psychomotor function, social
responsiveness, etc.). In some embodiments, the methods reduce or ameliorate
the
severity and/or duration of an ASM disorder and/or one or more symptoms
associated with the disorder. In some embodiments, the methods prevent the
recurrence of a symptom associated with an ASM disorder. In some embodiments,
the methods increase the survival rate of subjects after treatment.
Screening for and/or Diagnosing an ASM disorder
[0055] In various embodiments, disclosed herein are methods of screening
for and/or diagnosing an ASM disorder. In some embodiments, the ASM disorder
is
Niemann-Pick disease (NPD). In some embodiments, the disorder is NPD type A,
type B, and/or type C. In some embodiments, an ASM disorder (e.g., NPD) can be
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
screened for and/or diagnosed by measuring lyso-SPM levels in a biological
sample
taken from a subject.
[0056] In some embodiments, a method of screening for and/or diagnosing
an ASM disorder in a subject can comprise collecting a biological sample from
the
subject, measuring the level of lyso-SPM in the sample, comparing the level of
lyso-
SPM in the sample to a reference level, and detecting/diagnosing an ASM
disorder if
the level of lyso-SPM in the sample is elevated as compared to the reference
level.
In some embodiments, a reference level is the level of lyso-SPM measured in a
sample from a control subject who does not have an ASM disorder. In some
embodiments, an ASM disorder can be detected/diagnosed if the level of lyso-
SPM
in the biological sample from the subject is higher than a predetermined
reference
level. In some embodiments, an ASM disorder can be detected/diagnosed if the
level of lyso-SPM in the biological sample (e.g., a blood sample) is greater
than a
reference level of at least about 200-2000 ng/ml, such as greater than about
200
ng/ml, greater than about 300 ng/ml, greater than about 400 ng/ml, greater
than
about 500 ng/ml, greater than about 525 ng/ml, greater than about 575 ng/ml,
and/or
greater than about 700 ng/ml (e.g., greater than about 200, 250, 300, 350,
400, 450,
500, 525, 550, 575, 600, 625, 650, 700, 750, 800, 850, 900, 950, 1000, 1050,
1100,
1150, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 ng/ml, or any
concentration in between). In some embodiments, an ASM disorder can be
detected/diagnosed if the level of lyso-SPM in the biological sample (e.g., a
blood
sample) is greater than a reference level by a factor of about 1-10 fold.
[0057] Biological samples from various tissues can be used with the
screening and diagnostic methods described herein. For example, biological
samples from peripheral tissues, such as plasma, whole blood (e.g., dried
blood
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
31
spot), serum, skin, and/or urine can be used to monitor for elevated lyso-SPM
levels.
Biological samples from other tissues can also be used, e.g., spleen, lung,
liver,
heart, kidney and/or brain tissue. Samples from combinations of two or more
tissues
can be used (e.g., 2, 3, 4, 5, or more tissues). In some embodiments, an ASM
disorder (e.g., NPD) can be detected/diagnosed by measuring lyso-SPM levels in
a
biological sample taken from a peripheral tissue. In certain embodiments, the
peripheral tissue can be plasma, whole blood (e.g., a dried blood spot),
serum,
and/or urine. Use of a peripheral sample can avoid the need for invasive
procedures
such as a liver biopsy.
[0058] In various embodiments, the screening and/or diagnostic methods
disclosed herein can further comprise administering a therapeutic agent (e.g.,
an
enzyme replacement therapy) to a subject if an ASM disorder is
detected/diagnosed.
In some embodiments, the enzyme replacement therapy comprises administering a
rhASM or a modified rhASM to the subject.
Kit
[0059] In various embodiments, a kit is disclosed herein, comprising a
device for collecting a biological sample containing lyso-SPM and/or other
markers
of an ASM disorder, and instructions to use the kit to measure the level of
lyso-SPM
and/or other markers in the biological sample. In some embodiments, the device
for
collecting a biological sample can comprise a test tube, syringe, and/or other
container for storing a fluid sample, and/or a test strip, dipstick, etc. Any
other
device known in the art for collecting a biological sample can also be used.
In some
embodiments, the biological sample is a sample from a peripheral tissue, such
as
plasma, whole blood (e.g., dried blood spot), serum, skin, and/or urine.
Biological
samples from other tissues can also be collected, e.g., spleen, lung, heart,
liver,
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
32
kidney, and/or brain tissue, and the kit comprises a device for collecting a
sample
from the listed tissues. Samples from a combination of two or more tissues can
be
used.
[0060] In some embodiments, the kit can further comprise a device for
measuring the level of lyso-SPM and/or other markers in the biological sample.
For
example, the kit can include an antibody and/or other detection agents that
can be
used to detect the lyso-SPM or other markers in the biological sample. In some
embodiments, the detection agent is included in or on the tissue collection
device
(e.g., an antibody or indicator chemical impregnated on a test strip), while
in other
embodiments, the detection agent is provided separately from the collection
device.
[0061] In some embodiments, a kit can further comprise a device for
quantifying or semi-quantifying the level of lyso-SPM and/or other markers in
the
sample. For example, an agent (e.g., a colorimetric agent) can be provided
that
reacts with the detection agent to emit a detectable signal whose strength,
intensity,
color, etc. can be used to quantitatively or semi-quantitatively determine the
level of
lyso-SPM and/or other markers in the sample (e.g., by comparison to the signal
from
one or more reference samples). In some embodiments, the device can comprise a
device for separating lyso-SPM from the other components of the sample, e.g.,
using
liquid chromatography and/or mass spectrometry. In some embodiments, the
device
for quantifying the level of lyso-SPM and/or other markers in the sample is a
spectrometer, such as a mass spectrometer, e.g., LC/MS/MS, or an
electromagnetic
frequency spectrometer, e.g., UV-VIS, IR, or NMR.
[0062] In some embodiments, the kit can further comprise instructions to
compare the level of lyso-SPM and/or other markers in the sample to a
reference
level and to detect the presence of toxic levels of one or more metabolites
and/or an
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
33
adverse side effect during a treatment for an ASM disorder if the level of
lyso-SPM
and/or other toxicity markers in the sample are elevated as compared to one or
more
reference samples. In some embodiments, the kit can further comprise
instructions
to compare the level of lyso-SPM in the sample to the level in a reference
sample
and to screen for and/or diagnose an ASM disorder if the level of lyso-SPM in
the
sample is elevated as compared to the level in the reference sample.
[0063] In some embodiments, the kit can be used as part of a therapy for
and/or to diagnose an ASM disorder. In some embodiments, the ASM disorder is
NPD-A, NPD-B, or NPD-C.
Subject Populations
[0064] In various embodiments, a subject as used herein is a human who
is being screened for an ASM disorder. In various embodiments, a subject as
used
herein is a subject diagnosed with or treated for an ASM disorder in
accordance with
the methods provided herein is a human who has or is diagnosed as having a
disorder that results in excessive accumulation of lysosomal SPM in one or
more
organ of pathology. In some embodiments, the subject has one or more mutations
in
the gene encoding acid sphingomyelinase, e.g., a deletion, a frameshift, a
missense
mutation, and/or a nonsense mutation. In particular embodiments, a subject has
NPD. In one embodiment, the subject has NPD-A, NPD-B, or NPD-C.
[0065] In some embodiments, a subject has one or more mutations in the
SMPD 1 gene. In certain embodiments, the mutation is AR608 (deletion of
arginine
608). In some embodiments, the mutation is a missense mutation. In certain
embodiments, the missense mutation is L302P, H421Y or R496L. In other
embodiments, the mutation is a deletion that results in the deletion of one,
two,
three, or more amino acid residues. In specific embodiments, a subject treated
for an
WO 2014/197859
PCT/US2014/041405
34
ASM disorder in accordance with the methods provided herein has one or more of
the mutations shown in Table 1 in U.S. Application No. 2011/0052559
. See also Simonaro et al., Am. J.
Hum. Genet. 71: 1413-1419 (2002) for mutations in the acid sphingomyelinase
gene
(designated SMPD1).
[0066] In certain embodiments, a subject being screened for or
diagnosed
with or treated for an ASM disorder in accordance with the methods provided
herein
may endogenously expresses ASM but with about 2 to 5%, 5 to 10%, 5 to 15%, 5
to
20%, 5 to 30%, 20% to 30%, or 5 to 35% of the activity of normal (e.g., non-
mutated)
human ASM, e.g., ASM-1. In some embodiments, the subject endogenously
expresses ASM with less than 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or
1% of the activity of normal human ASM, e.g., ASM-1. See, e.g., U.S. Pat. Nos.
4.039,388, 4,082,781, 5,686,240, and 7,563,591, and International Publication
Nos.
WO 2007/078806 and WO 2006/058385,
for techniques that can be used to measure the activity of ASM; see
also the fluorescence-based, high-performance liquid chromatographic assay
described in He et al., Analytical Biochemistry 314: 116-120 (2003).
[0067] In various embodiments, a subject being screened for or
diagnosed
with or treated for an ASM disorder in accordance with the methods provided
herein
may display one or more symptoms of NPD. Symptoms of NPD can include, but are
not limited to, a distended abdomen, hepatomegaly, splenomegaly,
hepatosplenomegaly, neutropenia, pulmonary disease, lymphoadenopathy, the
presence of histochemically characteristic NPD foam cells, anemia (e.g.,
microcytic
anemia), thrombocytopenia, recurrent vomiting, chronic constipation, growth
failure
(e.g., decreased liner growth and body weight), delayed puberty, recurrent
bruising,
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
recurrent bleeding, atherogenic lipid profile (high cholesterol,
triglycerides, or [DL,
and/or low HDL), pain (headache, back, extremities, abdomen), fatigue, early
satiety,
low endurance, osteopenia, neurological manifestations, and respiratory
difficulties
(e.g., interstitial lung disease and/or shortness of breath). Neurological
manifestation
of NPD include cherry red spot, hypotonia, muscle weakness, psychomotor
retardation, spasticity, social unresponsiveness, irritability, and/or
seizures.
[0068] In certain embodiments, a subject being screened for or diagnosed
with or treated for an ASM disorder in accordance with the methods provided
herein
is a human infant. In other embodiments, the subject is a human child. In
certain
embodiments, the subject is a human adult (18 years or older). In certain
embodiments, the subject is a human female. In other embodiments, the subject
is a
human male. In certain embodiments, the subject is a human female who is not
pregnant or is not breastfeeding.
WO 2014/197859
PCT/US2014/041405
36
Examples
[0069] The following examples serve to illustrate, and in no way
limit, the
present disclosure.
Example 1: Materials and Methods
[0070] Whole blood used in the study was acquired from 20 previously
diagnosed NPD-B subjects following written informed consent and from 20
healthy
adults (purchased from ProMedDx, LLC, Norton, MA). Venous blood was drawn into
Vacutainer tubes (Becton, Dickinson and Company, Franklin Lakes, NJ)
containing
EDTA, shipped on cold packs overnight, and held at 4 C. Within 48 hours of
collection, the blood was mixed by inverting the tubes several times, and 75
[IL of
blood per spot was spotted onto Whatman 903 specimen collection paper and
dried
at room temperature for at least 4 hours.
[0071] To quantify lyso-SPM, 1-0-hexadecyl-(7,7,8,8-d4)-2-0-acetyl-sn-
glycery1-3-phosphorylcholine (Platelet-activating Factor C16-d4; PAF C16-D4,
Cayman Chemical Company, Ann Arbor, Michigan) was used as an internal
standard. A 3.2 mm punch of dried blood spots (DBS) was extracted in 200 I_
methanol/acetonitrile/water (80/15/5) containing 0.8 ng internal standard,
vortexed
for 30 minutes, and sonicated for 10 minutes. The eluent was cleared by
centrifugation for 5 minutes at 16,200 g and then 30 pt was injected into an
API
TM
Qtrap 4000 LC/MS/MS (AB Sciex, Toronto, Canada) system interfaced with an
TM
Agilent 1100 High Pressure Liquid Chromatography (H PLC) system (Agilent, Palo
Alto, CA). HPLC was performed with a normal-phase silica column in isocratic
mode
using a mixture of methanol/acetonitrile/water as the mobile phase. Mass
spectrometry (MS) was performed in multiple reaction monitoring (MRM) mode
with
the following transitions: m/z 465.4>184.1 for lyso-SPM and 528.5>184.1 for
PAF
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
37
C16-D4. To quantitate SPM, C12-SPM (Avanti Polar Lipids, Alabaster, Alabama)
was used as the internal standard. The extraction and LC/MS/MS procedures were
similar to those used for lyso-SPM except that the eluent was diluted 320-fold
before
injection and the twelve isoforms of SPM were monitored and summarized.
Example 2: Diagnosis of NPD
[0072] Although SPM levels are known to be elevated more than 10-fold in
the livers and spleens of NPD-B subjects, SPM levels in the plasma of NPD-B
subjects are not appreciably elevated and overlap with those of normal
controls. As
shown in FIG. 1A, the level of SPM in NPD-A and NPD-B patients was not
significantly elevated, as shown by the ratio of SPM concentration in dried
blood
spots (DBS) from NPD-A and NPD-B patients to the mean concentration value in
DBS from normal control samples. SPM is a major component of cell membranes
and lipoproteins, and the slight elevation of SPM in DBS from NPD subjects may
be
related to its already high levels and rapid turnover in the circulation.
[0073] Unlike SPM, lyso-SPM levels were clearly elevated in DBS from
NPD-A and NPD-B subjects. As shown in FIG. 1B, the level of lyso-SPM in NPD-A
and NPD-B patients was elevated, as shown by the ratio of lyso-SPM
concentration
in dried blood spots (DBS) from NPD-A and NPD-B patients to the mean
concentration value in DBS from normal control samples. The lyso-SPM level did
not correlate with the amount of residual ASM activity in DBS or with subject
age at
collection. In conclusion, lyso-SPM is increased in peripheral tissue (DBS)
from
NPD subjects at levels that are distinguishable from normal controls.
Example 3: Effect of Dose Escalation in Mouse
[0074] Previous studies in ASM knockout mice (Niemann-Pick model mice)
demonstrated that clinical symptoms of toxicity were not observed until single
doses
CA 02914751 2015-12-04
WO 2014/197859
PCT/1JS2014/041405
38
greater than or equal to 10 mg/kg were used. Nickerson et al., "Dose
Responsive
Toxicological Findings Following Intravenous Administration of Recombinant
Human
Acid Sphingomyelinase (rhASM) to Acid Sphingomyelinase Knock-out (ASMKO)
Mice," American Society of Human Genetics 2005; and Murray et al., "Elevations
of
Pro-Inflammatory Cytokines and Decreases in Cardiovascular Hemodynamics
Following Intravenous Administration of Recombinant Human Acid
Sphingomyelinase (rhASM) to Acid Sphingomyelinase Knock-out (ASMKO) Mice,"
Society of Toxicology 2006.
[0075] In the current study, ASM knockout mice were administered a
single intravenous dose of rhASM at one of three different concentrations: 0
mg/kg, 3
mg/kg (non-toxic dose, no clinically-apparent adverse effects observed), or 20
mg/kg
(toxic dose). 3 male and 3 female mice were assigned to each dosage group (18
total animals) and blood samples were collected at the times indicated in
Table 1.
Table 1
Pig2727
=
ireatment ,
mg/kg) Type Ttmepoinls
1 0 5 minutes and 6, 24, 48,
and 72 hours post-dose
2 rhASM 3 DBS 5 minutes and 6, 24, 48,
and 72 hours post-dose
3 20 5 minutes and 1, 4, 6,
and 9 hours post-dose
[0076] Lyso-SPM levels from DBS samples were quantified and showed
that levels increased with increasing rhASM dose concentrations, peaking for
the 3
mg/kg and 20 mg/kg treatment groups around 6 hours post-dose. See FIG. 2, a
histogram showing the fold elevation in lyso-SPM concentrations in DBS for the
WO 2014/197859
PCT/US2014/041405
39
three doses at the sampled post-dose time points, as compared to the
concentration
minutes after dosing. Surprisingly, the fold increase in plasma concentration
of
lyso-SPM in response to a toxic dose (20 mg/kg) of rhASM was markedly higher
than the fold increase in plasma concentration of lyso-SPM in response to a
non-
toxic dose (3 mg/kg) of rhASM. This result suggests that lyso-SPM is useful as
a
marker for gauging the toxic effects of a therapeutic agent that reduces the
level of
SPM accumulated in a patient with an ASM disorder.
Example 4: Comparison of Single Dose and Debulking Regimens
[0077] Dried blood spots were obtained from wild type (C57BU6) or ASM
knockout (ASMKO) mice following administration of a single dose or a debulking
dosing regimen of rhASM. Five ASMKO mice were given a single dose of 10 mg/kg
rhASM. Five C57BU6 and five ASMKO mice were treated using a debulking
regimen of 3mg/kg rhASM and then given a dose of 20mg/kg. Blood samples were
taken at the following time points: 5 minutes, 4 hours, 6 hours, 24 hours, and
72
hours post dose. The animals in the 10mg/kg dosing group had to be euthanized
after the 24 hour time point.
[0078] All 70 blood spot samples were prepared using the lipid
multiplex
extraction procedure and analyzed by LC/MS/MS. Briefly, single DBS spots were
TM
punched from each sample card and placed into individual eppendorf tubes. Two
hundred microliters of an 80:15:5 solution (MeOH:ACN:H20) was then added to
each tube before it was vortexed for 30 minutes, sonicated 10 minutes, and
centrifuged to spin down any particulates. A lyso-SPM calibration curve
(without
internal standard) was used to determine the concentration of lyso-SPM in each
sample.
Date Recue/Date Received 2020-11-03
CA 02914751 2015-12-04
WO 2014/197859
PCMJS2014/041405
[0079] The data in FIG. 3 show that lyso-SPM levels increased only in
the
ASMKO group that was treated with a single (high) dose of rhASM at 10 mg/kg,
in
contrast to the ASMKO group subjected to a debulking regimen. At such a high
dose, it is expected that at least 50% of the mice will die between 24 and 72
hours,
whereas all mice should survive under the debulking regimen. These results
suggest
that lyso-SPM could be useful as a marker for gauging the toxic effect of a
high dose
of a therapeutic agent.
Example 5: Human Testing
[0080] Blood samples were collected from Niemann-Pick patients being
treated with rhASM. A representative example is shown in FIG. 4. Samples were
collected pre-dose, and 24, 48, and 72 hours after administration of an
indicated
dose (0.1, 0.3, 0.6, 1, 2, or 3 mg/kg) of rhASM over a 26 week period (day 1,
week 2,
4, 6, 8, 10, 12, 14, and 26). At 26 weeks, samples were taken only pre-dose
and at
24 and 48 hours post dose. Levels of lyso-SPM were measured in ng/ml. The data
show a general downward trend in lyso-SPM levels following repeated doses at
higher concentrations, with fluctuations in the lyso-SPM level between the pre-
dose
and 72 hour post-dose time points following each individual dose. The earliest
post-
dose sample was taken after 24 hours, by which time a spike in the lyso-SPM
concentration following administration may not have been observed.
Administered
dosages may also have been below the concentration needed to observe a
significant spike in the lyso-SPM level following administration.
[0081] The preceding examples are intended to illustrate and in no way
limit the present disclosure. Other embodiments of the disclosed devices and
methods will be apparent to those skilled in the art from consideration of the
specification and practice of the devices and methods disclosed herein.
